Nicotinamide adenine dinucleotide (NAD+) is a cellular helper molecule administered by intravenous infusion, injection, or oral supplement to support cellular energy, genetic repair, and longevity. Human evidence for direct NAD+ has low certainty: hospital add-on trials show mixed heart failure results and faster hearing recovery, while most endurance and cognition studies tested vitamin B3 forms. High-dose infusions require slow administration over hours to prevent acute cramping and nausea. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Whole-Blood or Plasma NAD+ | No established target; tracked as change from individual baseline | Efficacy marker: confirms biochemical target engagement from NAD+ therapy |
| HDL-C | > 40 mg/dL in men; > 50 mg/dL in women (standard reference range) | Safety check and marker expected to change: high-dose intravenous NAD+ lowered HDL-C by 5.80 mg/dL at 30 days |
| ALT & AST | ALT: 7–56 U/L; AST: 8–33 U/L (standard reference range) | Safety check: values > 3× the upper limit of normal stop or exclude NAD+ use |
| Serum Creatinine & eGFR | Creatinine: 0.6–1.2 mg/dL; eGFR: ≥ 90 mL/min/1.73 m² (standard reference range) | Safety check: serum creatinine ≥ 225 μmol/L (~2.55 mg/dL) stops or excludes intravenous NAD+ |
| Plasma Homocysteine | 5–15 μmol/L (standard reference range) | Safety check: detects methyl-group depletion from nicotinamide N-methyltransferase (NNMT) clearance of high-dose NAD+, prompting methyl-donor adjustment |
| Resting Blood Pressure & Heart Rate | Blood pressure: < 120/80 mmHg; Heart rate: 60–100 beats/min (standard reference range) | Safety check and marker expected to change: excludes infusion at ≥ 180/110 mmHg and guides drip rate |
Cadence: Baseline prior to starting therapy; blood pressure and heart rate before and continuously during each intravenous infusion; lipid, liver, kidney, and homocysteine panels rechecked at 1 week and 4 weeks after a loading course, and every 3–6 months during maintenance therapy.